NasdaqGS:MLYS
NasdaqGS:MLYSBiotechs

How Mineralys Therapeutics' Improved Losses and $300 Million Shelf Filing Will Impact MLYS Investors

Mineralys Therapeutics reported third-quarter 2025 earnings, revealing a reduced net loss of US$36.93 million and a basic loss per share of US$0.52, both lower than the same period last year. Additionally, the company filed a US$300 million shelf registration, signaling potential future fundraising across multiple securities including common stock, preferred stock, debt, and warrants. To assess how these developments influence the company's investment narrative, we'll focus on how the...
NYSE:BABA
NYSE:BABAMultiline Retail

Did Alibaba’s 85% Surge in 2025 Reflect Its True Value After Regulatory Easing?

Curious if Alibaba Group Holding is still a smart buy after its huge run, or are you skeptical that it’s fully valued? Let’s dig into what the numbers and recent news are really telling us about where the stock stands today. Shares have rocketed up 85.7% year-to-date and 79.5% in the past year, but have slid by 4.9% over the last week and 5.6% over the past month. This highlights just how quickly sentiment can swing. Much of Alibaba’s recent price action stems from renewed optimism around...